Bipolar Disorder Treatment: Medication, Therapy, and Long-Term Care
Author: Ukrainian Psychological Hub · Published: October 9, 2026 · Editorial Policy
Bipolar disorder treatment combines phase-specific medication, structured psychological care, physical-health monitoring, and a sustained plan for preventing recurrence. What helps during acute mania differs from what helps during bipolar depression, and a medicine that treats an episode is not necessarily the preferred medicine to prevent the next one. A sound plan begins with the person's diagnosis, current symptoms, past episodes, treatment response, safety needs, and recovery goals. The National Institute of Mental Health and the international CANMAT/ISBD recommendations organize treatment around these distinct needs. [CANMAT]
Treatment is often highly effective in reducing symptoms and helping people live meaningful lives, although recovery may require changes in treatment and repeated follow-up. This article explains the principal options for bipolar I and bipolar II disorder, the evidence supporting them, clinical cautions, how clinicians monitor treatment, and the roles of psychotherapy, everyday routines, and crisis planning. It is intended as clinical education rather than individualized prescribing advice. [NIMH]
For additional clinical context, see Bipolar Disorder: Symptoms, Types, Diagnosis, and Treatment, Medications for Bipolar Disorder: Mood Stabilizers and Other Options and Lithium for Bipolar Disorder: Benefits, Risks, and Monitoring.
What are the goals of bipolar disorder treatment?
A comprehensive plan has immediate and long-term goals: resolve the current manic, hypomanic, mixed, or depressive episode; protect sleep, judgment, relationships, and physical safety; reduce the risk of future episodes; monitor medication effects; improve functioning; and support the person's own priorities. Some people recover fully between episodes while others experience residual depressive symptoms, problems with concentration, or social and occupational consequences that continue after the most acute symptoms settle. Those outcomes merit care in their own right. [NICE]
An August 2026 living umbrella review brought together systematic reviews of interventions across bipolar phases and age groups. It illustrates why conclusions must be separated by episode type, outcome, population, and certainty of evidence rather than treating every intervention called a mood stabilizer as equivalent. Clinical guidelines remain essential for translating the evidence into decisions that also account for risk, tolerability, and availability. [BMJ]
Begin with the correct diagnosis and episode
Bipolar I disorder requires a history of at least one manic episode. Bipolar II disorder involves hypomania and major depressive episodes without a history of full mania. Hypomania can markedly change sleep, energy, and behavior without the degree of impairment, psychosis, or hospitalization associated with mania. Bipolar II disorder can still cause severe and recurrent depression and substantial disability. Cyclothymic disorder has a sustained pattern of subthreshold mood symptoms that needs a different longitudinal assessment. These categories affect what clinicians treat and what outcomes they monitor. [NIMH]
Clinicians distinguish episodes from ordinary mood variation by examining a sustained change from baseline, accompanying symptoms, duration, severity, consequences, and longitudinal recurrence. A person's history may also reveal mixed features, psychosis, seasonal patterns, or rapid cycling. A period of unusually high energy by itself does not establish hypomania, and a questionnaire score is not a diagnosis. NICE recommends a detailed clinical history, relevant collateral information with permission, assessment of functioning, and evaluation for psychiatric and medical alternatives. [NICE]
Assessment also reviews whether substance use, stimulants or other medications, thyroid disease, sleep deprivation, ADHD, borderline personality disorder, anxiety, or psychotic disorders may explain or complicate symptoms. This differential matters because the risks of medication and the appropriate treatment sequence depend on the actual episode pattern. Medication changes are best made after a clinician has clarified both the present problem and the long-term course. [NICE]
Treatment differs by phase
Acute mania
Acute mania may involve markedly reduced need for sleep, accelerated speech and activity, grandiosity, risky spending, agitation, impaired judgment, or psychosis. Severe symptoms can disrupt the person's ability to evaluate risk or care for themselves. The priorities are urgent specialist assessment where indicated, a safer environment, restoration of sleep, rapid reduction of manic symptoms, and evaluation of medical or substance-related contributors. Hospital treatment may be necessary for severe mania or an immediate safety threat. [VA]
Evidence-supported antimanic medicines include several second-generation antipsychotics and mood-stabilizing agents such as lithium or divalproex. Depending on severity and prior response, a clinician may prescribe one medicine or combine an antipsychotic with a mood stabilizer, while watching for adverse effects and interactions. Antipsychotics differ in side effects and in the evidence for their use during other phases. A treatment that is highly effective for mania is not thereby established for acute bipolar depression. [CANMAT]
NICE recommends considering antipsychotic treatments for acute mania and reviewing existing treatment, including antidepressants that might aggravate an episode. Lamotrigine should not be offered as a treatment for mania. In presentations with mixed manic and depressive symptoms, close monitoring is particularly important. These decisions belong to the treating professional; patients should not independently stop or adjust prescribed medication. [NICE]
Bipolar depression
Bipolar depression can bring sustained low mood, diminished interest, fatigue, slowing, sleep and appetite changes, poor concentration, hopelessness, and sometimes suicidal thinking. Depression can account for much of the burden of bipolar illness even when mania has attracted more attention in the past. Clinicians establish whether the episode occurs in bipolar I or bipolar II disorder, whether it includes mixed features, and whether earlier treatment was associated with mood switching. [NIMH]
For acute bipolar I depression, CANMAT/ISBD discusses options including quetiapine, lithium, lamotrigine, lurasidone in appropriate regimens, and cariprazine, with further options considered according to evidence and patient circumstances. Not every medicine is equally effective, tolerated, available, or approved for every indication in every country. In an acute depressive episode, the decision depends on whether rapid symptomatic relief, long-term prevention, physical safety, or previous good response is the dominant consideration. [CANMAT]
For bipolar II depression, the evidence is evaluated separately. The CANMAT/ISBD 2023 update places quetiapine among the main first-line choices and discusses lithium, lamotrigine, and selected other options at subsequent levels of evidence. This distinction is one reason bipolar II should not be described as a mild form of bipolar I. The 2026 U-REACH evidence synthesis also emphasizes interpreting findings within the studied populations and treatment phases. [BMJ]
Psychological treatment adapted to bipolar disorder can support depression care and recovery, often alongside medication. Severe, psychotic, life-threatening, or treatment-resistant bipolar depression may call for specialist interventions, including consideration of electroconvulsive therapy when clinically indicated. An antidepressant alone is generally inappropriate for bipolar I depression because of potential mood destabilization; treatment choices require specialist review. [CANMAT]
Mixed features, rapid cycling, and psychotic symptoms
Mixed features mean symptoms from opposite mood poles occur together during an episode. Agitation, high energy, racing thoughts, and depressive distress may coexist. Rapid cycling refers to a defined recurrent episode pattern rather than daily emotional fluctuation. Psychotic features can occur during severe episodes and heighten the need for urgent assessment. NICE states that mixed affective states should be managed using the mania pathway while monitoring closely for depression, and recommends clinical reassessment of complex episode patterns. [NICE]
A person with frequent episodes does not automatically need an entirely separate or experimental drug regimen. The clinician examines the accuracy of the diagnosis, previous medicines and their effectiveness, sleep patterns, substance exposures, missed medication, and physical illness, then revises the approach according to the documented phase. The distinction between established care and preliminary findings is especially important in complex presentations. [VA]
Medications for bipolar disorder: an overview
The word mood stabilizer is useful shorthand but does not describe a uniform mechanism or an identical set of indications. Lithium, certain anticonvulsants, and several antipsychotics serve different clinical roles. Prescribing must also account for age, pregnancy potential, kidney or liver disease, metabolic risk, drug interactions, cost, access to blood testing, previous benefit, and what adverse effects the person can reasonably manage. Treatment comparisons should distinguish acute response from recurrence prevention. [CANMAT]
Lithium: acute and maintenance benefits
Lithium is an important medicine for acute mania and long-term prevention, with decades of clinical use. It is a first-line long-term pharmacologic recommendation in NICE guidance. Its effectiveness can vary across individuals and episode types. Some research associates lithium treatment with a reduction in suicidal behavior, but estimates and evidence certainty vary; no medication removes the need for ongoing suicide-risk assessment or a crisis response plan. [NICE]
Lithium requires measurement of blood levels because the effective range is close to concentrations that can cause toxicity. Before and during treatment, clinicians consider kidney function, thyroid function, calcium and other relevant laboratory values, fluid and sodium balance, concurrent medications, and pregnancy considerations. Serum testing is repeated after initiation or changes and then periodically according to stability and health needs. The U.S. prescribing information carries a boxed warning for lithium toxicity. [LITHIUM]
Dehydration, severe diarrhea or vomiting, significant salt or fluid changes, and interactions with some NSAIDs, diuretics, or blood-pressure medicines may increase lithium levels. Worsening tremor, unsteadiness, marked weakness, confusion, or pronounced drowsiness can signal toxicity and need prompt medical evaluation; severe symptoms warrant emergency care. Someone taking lithium should consult their prescribing team promptly during significant illness or before taking potentially interacting drugs. [LITHIUM]
Lamotrigine: depressive recurrence and serious rash risk
Lamotrigine has an evidence-supported role in maintenance treatment, particularly for preventing depressive recurrence in bipolar I disorder, and may be considered in selected bipolar depressive presentations. Its maintenance role is different from treating acute mania; NICE specifically advises against using lamotrigine to treat mania. Treatment is introduced gradually because the titration schedule is integral to safety, and interacting medicines can alter the correct schedule. [NICE]
Lamotrigine has a boxed warning for serious, potentially life-threatening skin reactions including Stevens–Johnson syndrome and toxic epidermal necrolysis. Rapid dose increases, excessive starting doses, and concurrent valproate can increase risk. Any new rash during treatment calls for immediate contact with a healthcare professional under the prescriber's safety instructions; a rash with fever, mucosal symptoms, blistering, or systemic illness needs urgent assessment. A patient should not restart lamotrigine after missed doses without professional guidance, because the titration plan may need reassessment. [LAMOTRIGINE]
Valproate and divalproex
Valproate formulations, including divalproex, have established roles in acute manic episodes and selected maintenance plans, but evidence and regulatory approvals vary by formulation, phase, and jurisdiction. Prescribers consider liver function, platelets, body weight, sedation, drug interactions, and other medical conditions. They also evaluate reproductive risks with particular care. The medication must not be assumed suitable for bipolar depression merely because it is effective in some manic presentations. [CANMAT]
U.S. divalproex labeling carries boxed warnings about hepatotoxicity, fetal harm, and pancreatitis. Exposure during pregnancy can cause major congenital malformations and adverse neurodevelopmental outcomes. UK guidance includes strict additional reproductive safety requirements, which differ from U.S. procedures. Pregnancy planning and contraception deserve advance discussion. If pregnancy occurs during treatment, the appropriate step is urgent specialist consultation rather than abrupt unsupervised withdrawal. [VALPROATE]
Severe abdominal pain, persistent vomiting, symptoms of liver injury, unusual bruising, or pronounced deterioration while taking valproate merit prompt clinical assessment. Choices for children, adolescents, and people who could become pregnant require population-specific guidelines and up-to-date regulatory advice. Medication decisions should explicitly weigh the risks of both exposure and inadequately treated severe bipolar episodes. [VALPROATE]
Antipsychotic medications
Several second-generation antipsychotics treat acute mania, some have evidence for bipolar depression, and some are used for maintenance or relapse prevention. These are distinct indications. Quetiapine appears in more than one phase-specific algorithm, whereas some other antipsychotics have stronger evidence for mania than for bipolar depression. Oral and long-acting injectable forms may also have different approved uses and practical advantages. [CANMAT]
Common monitoring considerations include weight and waist or BMI, blood pressure, blood glucose or A1c, blood lipids, sedation, restlessness or akathisia, movement symptoms, and other drug-specific effects. Prolactin changes and cardiac risks merit attention for selected medicines or patients. A clinician may obtain an ECG where the person's risk profile requires it. The goal is to control episodes while preserving metabolic, cardiovascular, neurologic, and everyday health. [NICE]
Some people benefit from long-acting injectable treatment when maintaining a daily oral schedule is difficult or recurrent mania poses particular risks. Selection depends on the specific drug, evidence, and patient preference. New emotional dulling, troublesome sedation, restlessness, or rapid weight gain should trigger a focused medication review rather than silent discontinuation. [CANMAT]
Antidepressants and the risk of mood switching
Antidepressants need special consideration in bipolar disorder. Major guidelines do not recommend antidepressant monotherapy for bipolar I depression. Antidepressant-associated mania or hypomania, mixed symptoms, and rapid cycling are potential concerns, although the degree of risk varies by person, agent, and study. In selected situations a specialist may consider an antidepressant alongside appropriate mood-stabilizing treatment, after reviewing prior switches and explaining uncertainty about benefits. [CANMAT]
Patients and relatives should tell the prescriber about new agitation, a sharply reduced need for sleep, unusual activation, racing thoughts, or risky behavior after a medication change. A treatment review might be necessary, but drug withdrawal or dosing changes should be directed by the treating clinician. Evidence from unipolar major depressive disorder cannot be assumed to apply to bipolar depression. [NICE]
How clinicians choose and change a medication regimen
Treatment planning involves a timeline of earlier episodes, medications previously tried, doses and duration of adequate trials, serious adverse effects, hospitalizations, psychosis, mixed features, prior response in relatives where relevant, and medical conditions. A clinician also considers current function, the person's preferences, availability of monitoring, potential pregnancy, and medication interactions. Shared decision-making is central because expected benefits and burdens can be quite different for two people with the same diagnosis. [NICE]
A partial response may call for additional time at an appropriate therapeutic exposure, a switch, or combination therapy, depending on the episode and risks. More medicines do not inherently mean better protection. Combinations can add sedation, metabolic risk, interactions, and medication burden. The decision should identify a clear target symptom or prevention outcome and a date for reassessment, with periodic consideration of whether simplification is possible safely. [CANMAT]
A first-line recommendation is a population-level starting point based on evidence and safety, not a guarantee of individual success. A drug can have an approved indication in one jurisdiction and be used off-label under a guideline elsewhere. Where studies are small, heterogeneous, or restricted to one bipolar subtype, the resulting uncertainty belongs in the treatment conversation. [BMJ]
Psychotherapy as part of bipolar treatment
Structured psychotherapy helps people learn about episodes, recognize early warning signs, support medication decisions, handle residual depression, improve problem-solving, and rebuild functioning. It is generally an adjunct to appropriate medical treatment, especially where there is a history of severe mania. A systematic review and component network meta-analysis in JAMA Psychiatry evaluated adjunctive psychotherapy for bipolar disorder and found benefits for some recurrence and depressive-symptom outcomes, with differences across interventions and study designs. [PSYCHOTHERAPY]
Psychoeducation
Psychoeducation means a sustained, practical treatment process rather than simply receiving a diagnosis leaflet. It can cover personal patterns of mania and depression, medications and monitoring, recognizing early signs, sleep disruption, coping with stress, and what relatives or clinicians should do if symptoms intensify. Structured group and family formats can support learning and follow-through. Evidence supports the role of well-developed bipolar-specific psychoeducation in relapse prevention. [PSYCHOTHERAPY]
Cognitive behavioral therapy
Bipolar-focused cognitive behavioral therapy adapts thoughts-and-behavior work to recurrent mood illness. It may help with depressive thinking, adherence barriers, avoidance, anxiety, routines, and early warning signs. Its evidence concerns adjunctive care and selected outcomes; CBT does not substitute for acute medical treatment when a person is severely manic, psychotic, or in immediate danger. The quality and consistency of effects differ among clinical trials. [PSYCHOTHERAPY]
Family-focused therapy
Family-focused interventions teach communication, collaborative problem-solving, illness knowledge, and responses to warning signs. They may also reduce family conflict and caregiver strain. Participation should be shaped by the person's wishes, consent, privacy, and capacity at the time. A relative can support the treatment plan without becoming the prescriber or assuming responsibility for every fluctuation in mood. [PSYCHOTHERAPY]
Interpersonal and social rhythm therapy
Interpersonal and social rhythm therapy, or IPSRT, addresses links among changes in interpersonal life, daily schedules, and sleep-wake rhythms. Patients work toward realistic regularity in routines and learn how significant life changes may affect stability. Some trials support its clinical usefulness, while confidence in comparative effects varies by outcome. It is an evidence-informed option selected according to symptoms, availability, and personal fit. [PSYCHOTHERAPY]
Maintenance treatment and long-term care
Maintenance care begins when acute symptoms resolve, rather than only after a future relapse. A clinician reviews whether the acute regimen should continue, which medicines have evidence for preventing the person's likely episode types, how to monitor physical health, and how psychotherapy or social support will continue. NICE recommends lithium as a first-line maintenance option, with antipsychotics and other strategies considered according to suitability and response. [NICE]
Lithium, lamotrigine, quetiapine, divalproex, and selected antipsychotics or combinations have different maintenance roles. Preventing mania and preventing depression are related but distinct outcomes. For instance, lamotrigine is more useful for some depressive-recurrence patterns than for acute mania, and a medicine with robust acute antimanic evidence cannot automatically be assumed to prevent depressive recurrence. Maintenance evidence needs its own review. [CANMAT]
Regular follow-up considers symptoms, quality of life, side effects, blood tests or metabolic monitoring where required, sleep, work and relationships, suicidal thoughts, alcohol or other substances, medical conditions, and whether the person can follow the plan. Primary care and psychiatric care may share physical-health responsibilities when responsibilities are explicit. A sustained stable period is an opportunity to optimize health and functioning, not a reason to abandon monitoring. [NICE]
Sleep, circadian rhythms, and lifestyle support
Sleep disruption can accompany, precede, or exacerbate mood episodes. Many people benefit from predictable sleep and waking times, awareness of how shift work or travel affects them, and prompt discussion of sudden reduced need for sleep combined with increased activity. Regularity should remain practical and supportive. Exhaustive tracking or punitive sleep rules may create unnecessary distress; the aim is to notice meaningful changes and respond earlier. [NIMH]
Physical activity, regular meals, reducing harmful alcohol and substance use, addressing anxiety or other coexisting illness, and maintaining supportive relationships can improve well-being. They do not replace medications in severe manic presentations. Social factors such as housing, financial stress, discrimination, work arrangements, and access to care also affect whether a treatment plan is workable. NICE explicitly includes physical and social recovery goals within ongoing care. [NICE]
Relapse prevention and a personal warning-sign plan
An effective written plan records past episode patterns, personalized early warning signs, triggers, useful coping measures, medications and monitoring requirements, preferred support people, specialist contact details, and indications for urgent assessment. For one person, approaching mania may begin with much less sleep and rapidly increasing spending; for another, depressive relapse may first appear as withdrawal and loss of interest. Careful observation of change from baseline is more useful than interpreting every ordinary mood variation as a relapse. [NICE]
A care plan can state which information may be shared with family or trusted friends if judgment becomes impaired. Where safe and appropriate, the person should help design the plan while stable. Changes in working hours, travel, medication access, and financial safeguards can be discussed in advance. Mood charts or digital tracking tools may support this process but are aids to clinical conversations, not stand-alone diagnostic tests. [NICE]
Recovery also concerns work, study, finances, identity, parenting, friendships, and relationships. An episode may resolve before someone feels ready to return to full responsibilities, and residual symptoms may need additional treatment. Rehabilitation, occupational support, family assistance, and realistic accommodations can help people regain chosen roles at a manageable pace. [NICE]
How long is bipolar disorder treated?
Bipolar illness can be recurrent, so many people benefit from long-term preventive treatment and regular reassessment over years. The duration of treatment depends on bipolar subtype, prior episode severity and frequency, time stable, tolerability, pregnancy planning, other medical conditions, and the likelihood and consequences of recurrence. Symptom improvement after an acute episode is not sufficient evidence that ongoing treatment is unnecessary. [NICE]
Stopping medication abruptly can increase recurrence risk and, for some drugs, introduce additional withdrawal or safety problems. If a treatment is ineffective, poorly tolerated, or no longer appropriate, the clinician should develop a medication-specific reduction or replacement plan and an increased-monitoring strategy. There is no universal safe discontinuation schedule for lithium, antipsychotics, antidepressants, and anticonvulsants. Patients should discuss missed doses or proposed medication changes with their clinician or pharmacist. [NICE]
What if treatment is not working?
Before concluding that a case is treatment-resistant, clinicians revisit the diagnosis and episode type, drug selection, dose and duration of an adequate trial, blood levels where relevant, side effects, interactions, sleep, missed doses, substance use, and coexisting illnesses. A new depressive episode despite an antimanic medicine may require a depression-specific intervention rather than simply increasing the same drug. Specialist consultation and a reassessment of the person's goals can guide the next step. [CANMAT]
Electroconvulsive therapy can be considered in selected situations such as severe or life-threatening mania, severe or resistant bipolar depression, catatonia, or urgent presentations requiring a potentially faster effect. A specialist discusses anesthesia, consent, possible memory effects, risks, and alternatives. Evidence and indications are different for mania and depression, and the intervention is never an automatic next step after a single unsuccessful drug trial. [NICE]
Ketamine-related interventions, transcranial magnetic stimulation, and light-based approaches have been investigated for bipolar depression. Available findings vary in quality, setting, and follow-up, and possible activation or mood switching must be considered. Newer evidence maps are useful for identifying promising signals, but the results for treatment-resistant unipolar depression cannot be transferred automatically to bipolar depression. These options require specialist discussion, and some remain investigational for the relevant bipolar indication. [BMJ]
Treatment in specific populations
Children and teenagers
Diagnosis and treatment in children and adolescents require developmentally informed specialty care. ADHD, sleep problems, trauma-related presentations, and other conditions may overlap with mood symptoms. Age-specific trials, medication approvals, school functioning, family context, and physical-health effects matter. Recommendations for adults must not be treated as automatically established in minors. NICE includes dedicated assessment and treatment recommendations for young people. [NICE]
Older adults
Older adults may have different patterns of medical illness, polypharmacy, kidney and thyroid vulnerability, cardiovascular risk, cognitive changes, and falls risk. The full range of treatments can still be considered, while blood testing, careful review of interactions, tolerability, and communication among clinicians may assume greater importance. Drug choice should respond to the person's health, not simply their age. [NICE]
Pregnancy and the postpartum period
Planning pregnancy, pregnancy itself, and the postpartum period call for coordinated perinatal psychiatry and obstetric care. Untreated severe mood episodes and medication exposure each carry consequences. Clinicians evaluate past postpartum episodes, medication-specific fetal and maternal risks, breastfeeding intentions, and the availability of timely specialist support. Valproate has particularly serious fetal-development risks and strict safety restrictions in many jurisdictions. Any pregnancy during treatment merits prompt contact with the treating team rather than abruptly stopping medication. [VALPROATE]
Coexisting anxiety, OCD, ADHD, and substance use
Co-occurring conditions can increase distress and alter prescribing decisions. A clinician may need to distinguish persistent attention symptoms from episodic activation, obsessions from mood-linked rumination, or substance-induced changes from spontaneous bipolar episodes. Coordinated treatment may involve specialists from several domains. An antidepressant or stimulant being considered for another condition warrants review of bipolar mood stability and prior switching, rather than applying the standard treatment pathway for the coexisting diagnosis without modification. [NICE] For a specific discussion of the diagnostic and medication issues that arise when the two conditions coexist, see OCD and bipolar disorder.
When to seek urgent help
Seek urgent medical or mental-health assessment for emerging severe mania, major loss of sleep with escalating agitation or risky judgment, psychosis, inability to meet essential needs, or serious deterioration into depression. Suicidal thoughts accompanied by intent, a plan, or imminent danger call for immediate emergency help. In the United States, call or text 988 for crisis support; if someone is in immediate danger, call 911 or go to an emergency department. Elsewhere, use local emergency and crisis services. [VA]
Relatives and trusted friends may help by describing observable changes, offering practical assistance, following a previously agreed crisis plan, and contacting professionals. Arguing over a person's experiences or attempting to manage a dangerous episode alone is rarely useful. Whenever possible, the immediate objective is appropriate professional assessment and safety, followed by a careful review of treatment and ongoing support. [NICE]
Practical questions to ask at an appointment
Ask which illness phase each prescribed medication is intended to treat, what change would count as a meaningful response, and when the plan will be reviewed. Discuss common and serious side effects, missed-dose instructions, potential interactions, required laboratory testing, pregnancy considerations, and what new symptoms should prompt urgent contact. If taking multiple medicines, ask why each remains necessary and whether monitoring covers their combined risks. [NICE]
For psychotherapy, discuss which bipolar-specific skills will be covered, whether individual, group, family-focused, or rhythm-based work fits, and how to connect early warning signs with an agreed response. For long-term recovery, make space for questions about work and study, financial protection during mania, support people, physical health, and personal priorities. Shared decisions work best when the patient knows both the expected benefits and the clinical trade-offs. [PSYCHOTHERAPY]
Frequently asked questions
What is the best treatment for bipolar disorder?
There is no one treatment that is best for every person or every phase. Acute mania, bipolar depression, and maintenance have distinct evidence bases. Lithium, selected antipsychotics, other phase-appropriate medicines, structured psychotherapy, and follow-up each have roles determined by the person's episodes, risks, and preferences. [CANMAT]
Can bipolar disorder be treated without medication?
Psychotherapy and self-management can make important contributions, but medication is generally central to evidence-based care for bipolar I disorder, particularly with severe mania or substantial risk of recurrence. People who cannot tolerate a medicine need a specialist review of alternatives and monitoring, rather than assuming psychotherapy alone provides equivalent antimanic protection. [NIMH]
Does bipolar disorder ever go away?
People can achieve prolonged remission and function well, although vulnerability to new episodes may remain. Treatment aims at sustained recovery, quality of life, and prevention as well as immediate symptom reduction. Long-term review can be valuable even during years of stable mood. [NICE]
Is bipolar II treatment different from bipolar I treatment?
Yes. Some options overlap, but bipolar II depression is evaluated separately from bipolar I mania and depression, and the study populations, approvals, and treatment priorities are not identical. Bipolar II should not be treated as simply less severe bipolar I. [CANMAT]
Does every antidepressant cause mania?
No. Switching risk varies by individual, medication, history, and clinical context, and the evidence is not uniform. Nonetheless, antidepressant monotherapy is generally avoided in bipolar I disorder, and clinicians monitor for activation, mixed symptoms, or hypomania when an antidepressant is used in selected circumstances. [CANMAT]
Is lithium safe over the long term?
Lithium can be an effective maintenance treatment for many people, but requires blood-level monitoring and assessment of kidney, thyroid, and other relevant functions. Safety depends on therapeutic concentration, health status, interactions, hydration, and follow-up. Symptoms suggesting toxicity need urgent medical evaluation. [LITHIUM]
Is lamotrigine effective for mania?
Lamotrigine is not an established acute antimanic treatment. Its important roles concern maintenance and selected depressive presentations, and careful titration is required because of the possibility of serious rash. [LAMOTRIGINE]
Can medication be stopped after a year without episodes?
A stable year alone does not determine whether stopping is safe. The person and clinician need to consider past episode severity, recurrence risk, benefits and harms of treatment, and a medication-specific plan for monitoring any proposed change. Abrupt discontinuation is especially concerning. [NICE]
How can family members help?
With the person's permission, family members may learn warning signs, support communication and treatment routines, participate in psychoeducation, and follow a crisis plan. Family-focused treatment can improve selected outcomes and help clarify what support the individual wants. [PSYCHOTHERAPY]